Redox active disulfides: The thioredoxin system as a drug target

Oncology Research

Volumn 9, Issue 6-7, 1997, Pages 351-356

  Lynn Kirkpatrick, D ^a   Ehrmantraut, Greg ^a   Stettner, Shawndra ^a   Kunkel, Mark ^a   Powis, Garth ^a  

^a UNIVERSITY OF REGINA   (Canada)

Author keywords

Antitumor; Combinatorial; Disulfides; Thioredoxin

Indexed keywords

ANTINEOPLASTIC AGENT; DISULFIDE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ANIMAL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER TRANSPLANTATION; CELL STRAIN HL 60; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; OXIDATION REDUCTION REACTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DISULFIDES; HL-60 CELLS; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OXIDATION-REDUCTION; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TRANSPLANTATION, HETEROLOGOUS;

EID: 0031308317     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gasdaska, P. Y.; Oblong, J. E.; Cotgreave, 1. A.; Powis, G. The predicted amino acid sequence of human Ihioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta 1218:292-296; 1994.
2. Laurent, T. C.; Moore, E. C.; Reichard, P. Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239:3436-3444; 1964.
3. Matthews, J. R.; Wakasugi, N.; Virelezier J.-L.; Yodoi, J.; Hay, R. T. Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cysteine62. Nucleic Acids. Res. 20:3821-3830; 1992.
4. Lundström, J.; Holgren, A. Protein disulfide-isomerase is a substrate for thioredoxin reductse and has thioredoxin-like activity. J. Biol. Chem. 265:9114-9120; 1990.
5. Wakasugi, N.; Tagaya, Y.; Wakasugi, A.; Mitsui, M.; Maeda, M.; Yodoi, J.; Tursz, T. Adult T-cell leukemiaderived factor/thioredoxin produced by both human Tlymphotropic virus type 1 and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-l and interleukin-2. Proc. Natl. Acad. Sci. USA 87:8282-8286; 1990.
6. Yodoi, J.; Tursz, T. ADF, a growth-promoting factor dervied from adult T cell leukemia and homologous to thioredoxin: Involvement in lymphocyte immortalization by HTLV-1 and EBV. Adv. Cancer Res. 57:381-411; 1991.
7. Powis, G.; Oblong, J. E.; Gasdaska, P. Y.; Berggren, M.; Hill, S.; Kirkpatrick, D. L. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol. Res. 6:539-544; 1994.
8. Oblong, J. E.; Berggren, M.; Gasdaska, P. Y.; Powis, G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem. 269:11714-11720; 1994.
9. Gasdaska, J. R.; Berggren, M.; Powis, G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 6:1643-1650; 1995.
10. Berggren, M.; Gallegos, A.; Gasdaska, J. R.; Gasdaska, P. Y.; Warneke, J.; Powis, G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:3459-3466; 1996.
11. Fujii, S.;' Nanbu, Y.; Nonogaki, H.; Konishi, I.; Mori, T.; Masutani, H.; Yodoi, J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 68:1583-1591; 1991.
12. Nakamura, H.; Masutani, H.; Tagaya, Y.; Yamauchi, A.; Inamoto, T.; Nanbu, Y.; Fujii, S.; Ozawa, K.; Yodoi, J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69:2091-2097; 1992.
13. Ericson, M. L.; Horling, J.; Wendel-Hansen, V.; Holmgren, A.; Rosen, A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res. 11:201-207; 1992.
14. Rubartelli, A.; Bajetto, A.; Allavena, G.; Wollman, E.; Sitia, R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J. Biol. Chem. 267: 24161-14164;1992.
15. Rubartelli, A.; Bonifaci, N.; Sitia, R. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res. 55:675-680; 1995.
16. Gallegos, A.; Gasdaska, J. R.; Taylor, C. W.: PaineMurrieta, G. D.; Goodman, D.; Gasdaska, P. Y.; Berggren, M.; Briehl, M. M.; Powis, G. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res. 56:5765-5770; 1996.
17. Kirkpatrick, D. L. Modification of antitumor disulfide cytotoxicity by glutathione depletion. Cancer Res. 47:4391-4395; 1987.
18. Kirkpatrick, D. L. Kinetic studies of the interaction of glutathione with four antitumor diuslfides: Possible mechanism for cellular GSH depletion. Chem. Biol. Interact. 69:225-234; 1989.
19. Coshan-Gauthier, R.; Kirkpatrick, D. L. Modulation of disulfide antitumor activity in Balb/c mice through glutathione depletion. Exp. Cell Biol. 57:273-280; 1989.
20. Kirkpatrick, D. L.; King, K. M. Inhibitory effect of cytotoxic disulfides on membrane NaVK ATPase. Biochem. Pharmacol. 39:1484-1487; 1990.
21. Kirkpatrick, D. L.; King, K. M.; Abu Sa'da, I.; Kelln, R. A.; Richardson, M. E.; Siemann, D. W. Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture. Anticancer Drugs 3:651-658; 1992.
22. Kirkpatrick, D. L.; Abu Sa'da, I.; Chernoff, W.; Kuperus, M. Disulfide cytotoxicity under hypoxia. Oncol. Res. 6:545-552; 1994.
23. Kirkpatrick, D. L.; Jimale, M. L.; King, K. M.; Chen, T. Synthesis and evaluation of imidazolyl disulfides for selective cytotoxicity to hypoxic EMT6 tumor cells in vitro. Eur. J. Med. Chem. 27:33-37; 1992.
24. Powis, G.; Kirkpatrick, D. L.; Angulo, M.; Gasdaska, J. R.; Broome Powell, M.; Salmon, S. E.; Montfort, W. R. Thioredoxin redox signalling: A novel target for anticancer drug development. Anticancer Drugs 7(Suppl. 3):121-126; 1996.
25. Oblong, J. E.; Chantier, E. L.; Gallegos, A.; Kirkpatrick, D. L.; Chen, T.; Marshall, N.; Powis, G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl imidazolyl disulfide analogues. Cancer Chemother. Pharmacol. 34:434-438; 1994.
26. Gasdaska, J. R.; Hill, S.; Kirkpatrick, L.; Montfort, W.; Kuperus, M.; Berggren, M.; Powis, G. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys"-Ser mutation. Biochem. Pharmacol. 52:1741-1747; 1996.
27. Boyd, M. R. Status of implementation of the NCI human tumor cell line in vitro primary drug screen. Proc. Am. Assoc. Cancer Res. 30:652-654; 1989.
28. Paull, K. D.; Lin, C. M.; Malspeis, L.; Hamel, E. Identification of novel anlimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 52:3892-3900; 1992.
29. Kunkel, M. W.; Kirkpatrick, D. L.; Johnson, J. I.; Powis, G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signalling as potential anti-cancer drugs. Cancer Chemother. Pharmacol. (in press).
30. McConkey, D. J. Regulation of apoptosis in thymocytes. Cancer Bull. 46:146-152; 1994.
31. Wang, Y.; Szekely, L.; Okan, I.; Klien, G.; Wiman, K. G. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431; 1993.
32. Kirkpatrick, D. L.; McCabe, J.; Kuperus, M. Stimulation of apoptosis by a redox active disulfide. Proc. Am. Assoc. Cancer Res. 36:2469; 1995.
33. Kuperus, M.; Kirkpatrick, D. L. Interaction of redox active disulfides with the autocrine growth factor, human thioredoxin. Proc. Am. Assoc. Cancer Res. 36:2541; 1995.
34. Kirkpatrick, D. L.; Kuperus, M.; Dowdeswell, M.; Angulo, M.; Powis, G. Antitumor activity of inhibitors of a novel signaling pathway: Thioredoxin/thioredoxin reductase. Proc. Am. Assoc. Cancer Res. 38:4115; 1997.
35. Borman, S. Combinatorial chemists focus on small molecules, molecular recognition, and automation. Chem. Eng. News 74: 29-64; 1996.